Chhavi Jain

News

PAM50-based score identifies low-risk subset with node-positive early-stage breast cancer

Author:: Chhavi Jain

Publish date: February 8, 2018

About 37% of patients with a single positive lymph node and 15% of patients with two positive nodes were identified as low risk, with very favorabl...

News

CLL Index proves accurate in predicting survival, time to treat

Author:: Chhavi Jain

Publish date: February 5, 2018

A meta-analysis shows that the CLL-IPI is a useful tool with chemoimmunotherapy, but data is lacking about its use with targeted therapies.

News

Hodgkin lymphoma survivors are at an increased risk of subsequent ER-negative breast cancer

Author:: Chhavi Jain

Publish date: January 30, 2018

Subsequent risk of estrogen receptor–negative breast cancer was elevated irrespective of the type of therapy given for Hodgkin lymphoma.

News

Retroperitoneal lymphadenectomy did not impact OS and DFS for high risk, nonmetastatic renal cell carcinoma

Author:: Chhavi Jain

Publish date: January 29, 2018

In a secondary analysis of the ASSURE adjuvant trial, there was no relative improvement in overall survival for lymphadenectomy in high-risk RCC.

News

Analysis of Twitter lung cancer content reveals opportunity for clinicians

Author:: Chhavi Jain

Publish date: January 25, 2018

Twitter conversations focused on treatment and end of life were significantly less likely to integrate cues for personal activity.

News

OS similar among mRCC patients enrolled in clinical trials across different geographic regions

Author:: Chhavi Jain

Publish date: January 17, 2018

Despite different baseline characteristics, OS was similar among patients enrolled in clinical trials across different geographic regions.

News

Refractory FGFR-altered cholangiocarcinoma responds to FGFR kinase inhibitor

Author:: Chhavi Jain

Publish date: December 2, 2017

A median progression-free survival of 5.8 months is encouraging in patients with this aggressive cancer, and this targeted therapy warrants further...